VEGF-B, is a member of the VEGF family that primarily binds to VEGFR-1 and neuropilin-1. Unlike VEGF-A, it is less involved in direct angiogenesis but plays a key role in vascular survival, permeability, and inflammatory modulation in ocular tissues. By blocking VEGF-B, reflocibart aims to reduce pathological vascular leakage and inflammation while potentially preserving physiological vascular functions, offering a targeted approach for managing retinal edema and neovascularization.